Growing community of inventors

Paris, France

Rita Raisman-Vozari

Average Co-Inventor Count = 4.86

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 1

Rita Raisman-VozariBruno Figadere (3 patents)Rita Raisman-VozariFanny Schmidt (2 patents)Rita Raisman-VozariLaurent Ferrie (2 patents)Rita Raisman-VozariPierre Champy (1 patent)Rita Raisman-VozariPatrick Michel (1 patent)Rita Raisman-VozariJulia Sepulveda (1 patent)Rita Raisman-VozariGael Le Douaron (1 patent)Rita Raisman-VozariGaël Le Douaron (1 patent)Rita Raisman-VozariClémence Rose (0 patent)Rita Raisman-VozariPatrick Pierre Michel (0 patent)Rita Raisman-VozariRita Raisman-Vozari (3 patents)Bruno FigadereBruno Figadere (7 patents)Fanny SchmidtFanny Schmidt (3 patents)Laurent FerrieLaurent Ferrie (2 patents)Pierre ChampyPierre Champy (2 patents)Patrick MichelPatrick Michel (1 patent)Julia SepulvedaJulia Sepulveda (1 patent)Gael Le DouaronGael Le Douaron (1 patent)Gaël Le DouaronGaël Le Douaron (1 patent)Clémence RoseClémence Rose (0 patent)Patrick Pierre MichelPatrick Pierre Michel (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Centre National De La Recherche Scientifique (3 from 5,072 patents)

2. Institut National De La Sante Et De La Recherche Medicale (1 from 1,743 patents)

3. Assistance Publique-hopitaux De Paris (1 from 317 patents)

4. Sorbonne Université (1 from 236 patents)

5. Université Paris—sud (1 from 99 patents)

6. Université Paris-Sud 11 (1 from 42 patents)

7. Institut Du Cerveau Et De La Moelle Epiniere (1 from 4 patents)

8. Université Paris-Saclay (78 patents)


3 patents:

1. 10550115 - 1, 4, 8-triazaphenanthrene derivatives for the treatment of neurodegenerative disorders

2. 9434701 - Aminoquinoxaline derivatives for treatment of neurodegenerative diseases

3. 8614246 - Indole derivatives for treating neurodegenerative diseases

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/14/2025
Loading…